Conclusion of a non-exclusive discount agreement according to § 130a paragraph 8 of the German Civil Code V for drugs containing the active substance golimumab (ATC code: L04AB06) within the period from 1.10.2021 to 30.9.2023 with the possibility of concluding the contract at any time during the term (“open-house model”).
The contractual partners can be viewed at: https://www.aok-gesundheitpartner.de/nds/arzneimittel/rabatt/index_03504.html?bl=nds
The AOK — The Health Fund for Lower Saxony intends until exclusive contracts come into force after a public tender in accordance with the regulations of the 4th part of the GWB, not exclusive drug discount contracts for the active substance golimumab (ATC code: L04AB06) with as many market participants as possible (pharmaceutical entrepreneurs or communities of pharmaceutical entrepreneurs) in the so-called “open house model”.
AOK Lower Saxony will not make a selection decision and will submit an identical contract offer to any interested pharmaceutical company. In the open-house model, uniform conditions apply to all participants. Contract content, conditions and access procedures are uniform — individual negotiations are generally not conducted. The contract terms are a maximum of twenty-four months, and the earliest start of the contract is October 1, 2021. All contracts end no later than September 30, 2023, regardless of the date of the respective contract conclusion. Joining or concluding a contract can take place on the first of a month within the twenty-four month period. There is a right of termination for 6 weeks at the end of the month. AOK Niedersachsen reserves the right to replace the non-exclusive open-house discount contracts with exclusive discount contracts even during the contract period. With the entry into force of advertised exclusive discount contracts, the open-house contracts are terminated in accordance with the contractual regulations, i.e. the open-house contracts end automatically. According to the experience of AOK Lower Saxony, exclusive discount contracts usually enter into force 6 to 8 months after the publication of the relevant tender notice in the supplement to the Official Journal of the European Union. Future contractors in the open house model are asked to regularly inform themselves about these tender notices in the supplement to the Official Journal of the European Union.
Interested pharmaceutical companies can request the contractual documents and the contractual terms and conditions at the contact address given under I.1).
Contracts for the active substance golimumab (ATC code: L04AB06) will be concluded for the first time with effect from 1.10.2021. Interested parties wishing to become a contractual partner on this date must submit the contract documents to be submitted to the address specified in the contract documents by 27.8.2021. It depends on access at AOK Lower Saxony. Contracts can be concluded later on the first of each month during the twenty-four-month maximum period. In terms of organization, an advance of usually 35 calendar days is required by AOK to ensure the necessary work, such as reporting the contract in the Lauer Taxe®. The exact deadline for receipt will be announced with the contract documents. This publication does not constitute the award of a public contract within the meaning of Directive (2014/24/EU) or the GWB. In order to ensure a broadest degree of transparency for the intended conclusion of contracts, the publication is made in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process name “open procedure”, are solely due to the use of this announcement form and the publication platform. This does not involve any further significance, in particular subjection to subcontracting regulations, unless they are mandatory for legal reasons.